The Ultrix Quadri vaccine produced by the Nacimbio Holding of Rostec State Corporation has been approved by the Russian Ministry of Health for the vaccination of people over 60 years of age. Earlier, the vaccine was allowed to be used for young children and pregnant women. Thus, in the current epidemic season, it has become available to patients of all ages.

The Ultrix Quadri vaccine protects against four circulating strains of the influenza virus – two subtypes of A virus (A/H1N1 + A/H3N2) and two influenza B viruses of 2 lines (B/Yamagata + B/Victoria). One vaccine dose contains 15 μg of antigens of each strain – in total 60 μg. This is the composition recommended by the World Health Organization (WHO) for inclusion in inactivated vaccines. Ultrix Quadri is manufactured at the FORT plant of the Nacimbio Holding of Rostec State Corporation using a full-cycle technology in compliance with international GMP standards. The vaccine is free of preserving agents, stabilizers or adjuvants – the substances used to enhance the immune response.

The ‘60+’ age group was the last in the vaccine clinical trials procedure, which confirmed its high protective properties. “All volunteers of Ultrix Quadri developed high antibodies to influenza viruses, while none of them had any complications or serious side effects,” said Andrey Zagorsky, General Director of the Nacimbio Holding.

Biopharmaceutical company FORT is the largest manufacturer of influenza vaccines in Russia. The enterprise annually produces more than 30 million doses of medicines for influenza prevention. Ultrix Quadri is used in Russia in accordance with the state plan for transition to the use of quadrivalent influenza vaccines. In 2020, the vaccine entered international markets.